Silex Systems Limited · ASX:SLX
Silex Systems — Investor Presentation (February 2025)
21 slides from Silex Systems's investor presentation, Feb 21, 2025
Slide 1: Investor Presentation
For personal use only Investor Presentation 21 February 2025 Dr Michael Goldsworthy CEO/Managing Director Silex Systems Limited ASX: SLX OTCQX: SILXY www.silex.com.au www.silex.com.au 1
Slide 2: Forward Looking Statements and Risk Factors
Forward Looking Statements and Risk Factors About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) Silex Systems Limited ABN 69 003 372 067 (Silex or Company) is a technology commercialisation company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company’s
Slide 3: Our Mission: commercialise the SILEX laser enrichment technology
Our Mission: to commercialise the unique SILEX laser enrichment technology for application to: For personal use only Uranium production and Silicon enrichment Medical isotope enrichment enrichment (silicon quantum computing) (new cancer therapies) (nuclear power) Our strategy is focused on extractin
Slide 4: Evolution of Enrichment Technology
Evolution of Enrichment Technology 1st Generation Technology 2nd Generation Technology 3rd Generation Technology For personal use only Gaseous Diffusion Centrifuge SILEX Laser Very low efficiency – tails legacy Modest efficiency High efficiency and throughput High cost Moderate cost Anticipated to b
Slide 5: Recent Highlights and Developments
Recent Highlights and Developments Global Laser Enrichment (GLE) / SILEX Uranium Enrichment Technology Project: • GLE and Silex continued to advance the technology demonstration program for the SILEX uranium enrichment technology. Preliminary testing commenced in late CY2024 and triggered some minor
Slide 6: Primary Focus on GLE Commercialisation
Primary Focus on GLE Commercialisation Uranium production and enrichment for nuclear fuel For personal use only • Global nuclear fuel industry undergoing disruptive bifurcation, intensifying the nuclear renaissance in the Western world • GLE and Silex advancing SILEX technology commercialisation und
Slide 7: Nuclear Fuel Supply Chain and Evolving Issues
Nuclear Fuel Supply Chain and Evolving Issues The Nuclear Fuel Supply Chain For personal use only SILEX/GLE Opportunities Issues facing the Global Nuclear Fuel Supply Chain: • Western supply chain recent history – curtailments and under-investment in resources and production capacity • Supply chain
Slide 8: US and EU Nuclear Fuel Requirements Supplied by Russia
US and EU Nuclear Fuel Requirements Supplied by Russia Russian Share of Global EU Nuclear Fuel US Nuclear Fuel Production Capacity1 Supplied by Russia2 Supplied by Russia1,3 Uranium (U3O8) ~14% ~23% ~12% For personal use only Conversion ~22% ~27% ~18% Enrichment (SWU) ~44% ~38% ~27% • Major concerns
Slide 9: Favourable Nuclear Fuel Market Price Trends
Favourable Nuclear Fuel Market Price Trends For personal use only Source: UxC • Global nuclear fuel markets tightening as they bifurcate in response to Russia’s invasion of Ukraine and nuclear fuel sanctions and prohibitions • Uranium term prices reflect the significant increase in term contracting
Slide 10: US Support for GLE's Commercialisation Activities
US Support for GLE’s Commercialisation Activities US Government policies support nuclear as a critical energy source: Inflation Reduction Act Nuclear Fuel Security Prohibiting Russian Accelerating For personal use only (IRA) (2022) – US$700m Act (NFSA) (2023) – Uranium Imports Act Deployment of in s
Slide 11: Status of SILEX Technology Pilot Demonstration Project
Status of SILEX Technology Pilot Demonstration Project1 Significant progress towards pivotal TRL-6 technology demonstration continues Integrated TRL-6 Pilot Demonstration Facility: • Integrated large-scale Pilot Demonstration Facility built and commissioned, including For personal use only SILEX Tec
Slide 12: GLE's Tentative Timeline for Commercialisation of SILEX technology
GLE’s Tentative Timeline for Commercialisation of SILEX technology1 2024 2025 2026 2027 2028 2029 2030 TRL-62 T ETCEHCNHONLO OLGOYGM YAT MU ATR AT U RI AT O NI O TRNL - 3 T R L7 -, 87 ,A8NADNM D RML R - 7L, 8 - 7, 9, 8 , 9 3 For personal use only 4 5 UUSS NNRRCC4 PPLLA ANNT T L LIIC CEENNCCEE FFOOR
Slide 13: GLE's PLEF Commercial Plant Opportunity
GLE’s PLEF Commercial Plant Opportunity The PLEF Triple Opportunity Paducah Laser Enrichment Facility (PLEF) – an opportunity to deploy the SILEX technology in the US • PLEF UF6 Production: Production of up to 5 million pounds (equivalent) natural grade uranium (as UF6) annually for up to 30 years –
Slide 14: GLE's Commercialisation Activities: Paducah site and licensing
GLE’s Commercialisation Activities for the SILEX technology 1 Paducah, KY site acquisition and commercial plant licencing activities: • GLE acquired a 665-acre site for the planned PLEF in November 2024 • Site is strategically located adjacent the US DOE’s former first-generation Paducah Gaseous For
Slide 15: GLE's Commercialisation Activities: Wilmington facility
GLE’s Commercialisation Activities for the SILEX technology1 GLE corporate and classified manufacturing facility in Wilmington, NC: For personal use only GLE HQ and Classified Manufacturing Facility – Wilmington, NC 1. 1. GLE’s progress to commercialisation is dependent on several factors, including
Slide 16: GLE's Potential PLEF Commercial Plant Opportunities
GLE’s Potential PLEF Commercial Plant Opportunities1 For personal use only Source: GLE – PLEF Potential Commercial Plant (conceptual only) 1. Dependent on various factors, including, but not limited to: technology demonstration outcomes, market conditions, licensing, industry and government support,
Slide 17: PLEF UF6 Production Opportunity
PLEF UF6 Production Opportunity (Natural UF6 production from tails) Akin to a ‘Tier 1’ Aim to commence Equivalent U3O8 Uranium Resource2 Production For personal use only initial commercial Based on low cost and operations ahead of longevity of production Up to 5 million lbs p.a. for up to 30 years o
Slide 18: GLE Value Proposition for Silex
GLE Value Proposition for Silex1 1) GLE Equity – Minimum 25%: • Silex currently holds 51% – Cameco has a call Option to acquire an additional 26% at fair market value • Option window opened 1 February 2023 – closes 30 months after successful TRL-6 demonstration For personal use only • Silex has a si
Slide 19: Significant Additional Opportunities
Significant Additional Opportunities For personal use only Silicon enrichment Medical isotope enrichment (silicon quantum computing) (new targeted beta cancer therapies) • SILEX technology proven capable of producing highly enriched silicon • Medical isotope project aiming to develop a process to en
Slide 20: Summary
Summary • GLE’s path to market is underpinned by the PLEF UF6 Project for cost effective production of natural uranium (in the form of UF6) and significant value of conversion contained in DOE’s legacy depleted UF6 tails inventories • The ‘Triple Opportunity’ includes potential to add SILEX producti
Slide 21: Thank you
For personal use only Thank you www.silex.com.au www.silex.com.au 21
Silex Systems — Investor Presentation (February 2025) on 6ix